Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
Titel:
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
Auteur:
Nabholtz, J.M. Abrial, C. Mouret-Reynier, M.A. Dauplat, M.M. Weber, B. Gligorov, J. Forest, A.M. Tredan, O. Vanlemmens, L. Petit, T. Guiu, S. Van Praagh, I. Jouannaud, C. Dubray-Longeras, P. Tubiana-Mathieu, N. Benmammar, K.E. Kullab, S. Bahadoor, M.R.K. Radosevic-Robin, N. Kwiatkowski, F. Desrichard, A. Cayre, A. Uhrhammer, N. Chalabi, N. Chollet, P. Penault-Llorca, F.